MarginsXMarginsX
Home › Markets › Health Care › ERNA

Ernexa Therapeutics Inc. (ERNA)

ERNA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.69
+0.60% on the day
Market cap
$2.9M
Nano cap
Revenue · 2024
$582K
+755.9% on 2023
Net income · 2024
-$44.5M
-7652.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/0001493152-26-010102-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerERNA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000748592
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$582K
Net income-$44.5M
Operating income-$15.7M
Net margin-7652.7%
Operating margin-2693.1%
Revenue growth+755.9%
Cash$1.7M
Total assets$5.3M
P/E (computed)Net income was not positive
P/S (computed)4.9×

Warning signs

Cash runway
6.2 months
$5.6M cash at September 30, 2026
Share count, 1 year
+439.1%
2025-11-07 to 2026-11-06 · +11631.4% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In connection with preparing the financial statements as of and for the three and nine months ended September 30, 2026, the Company evaluated whether there are conditions and events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued."
10-Q 2026-11-06
Cash and burn$5.6M cash; operating cash flow -$2.7M a quarter.Report 2026-09-30
Shares outstanding1,692,550 (2026-11-06); 7,848,889 a year earlier; 5,410,331 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-375 overall).Cover page 2026-11-06
Reverse splits, 3 years2; latest 1-for-25 on 2026-05-04Source 2026-05-04
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-02-10
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-03-20
AuditorHaskell & White LLP, Irvine, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-07-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$2.9M-$3.2M$5.6MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2026
2026-06-30
Not filed-$4.0M-$4.2M$5.0MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$5.5M-$2.3M$9.2MNo debt tagsNeeds four quarters10-Q 2026-05-11
Q4 2025
2025-12-31
Not filed-$1.5M-$1.1M$1.9MNo debt tagsNeeds four quarters10-K 2026-03-13
Q3 2025
2025-09-30
Not filed-$1.2M-$1.3M$3.0MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2025
2025-06-30
Not filed-$3.1M-$2.5M$4.3MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$8.2M-$2.1M$1.9M$2.3MNeeds four quarters10-Q 2026-05-11
Q4 2024
2024-12-31
$1K-$5.8M-$3.5M$1.7MNo debt tags$582K10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-03-16
Latest annual report10-K2026-03-13
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-10-15
Latest proxyDEFA14A2026-05-11

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.6%
1 month-24.0%
3 months-60.9%
Year to date-94.4%
1 year-95.7%
From 52-week high-95.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
ERNAWErnexa Therapeutics Inc. Warrants$0.0257

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
EOCNEocene Ltd.$2.53+5.86%$2.6M
REVBRevelation Biosciences Inc.$3.82-10.43%$2.6M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier